INSM - INSMED Inc
IEX Last Trade
70.67
-0.505 -0.715%
Share volume: 22,876
Last Updated: Fri 27 Dec 2024 02:30:07 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.33%
PREVIOUS CLOSE
CHG
CHG%
$71.18
-0.51
-0.71%
Fundamental analysis
38%
Profitability
41%
Dept financing
25%
Liquidity
66%
Performance
30%
Performance
5 Days
-0.08%
1 Month
-6.80%
3 Months
-3.21%
6 Months
2.25%
1 Year
127.37%
2 Year
271.02%
Key data
Stock price
$70.67
DAY RANGE
$69.89 - $71.70
52 WEEK RANGE
$23.75 - $80.53
52 WEEK CHANGE
$122.21
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: William H. Lewis
Region: US
Website: insmed.com
Employees: 740
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: insmed.com
Employees: 740
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1.
Recent news